Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.anaerobe.2020.102169 http://scihub22266oqcxt.onion/10.1016/j.anaerobe.2020.102169 32058277!ä!32058277 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Anaerobe 2020 ; 62 (ä): 102169 Nephropedia Template TP {{tp|p=32058277|t=2020. Susceptibility of Cutibacterium acnes to topical minocycline foam |pdf=|usr=}}{{32058277}} gab.com Text Susceptibility of Cutibacterium acnes to topical minocycline foam JO: Anaerobe http://www.kidney.de/pget.php?&tw=1&pmid=32058277 #FOAvip FMX101 4% minocycline foam (FMX101 4%) is a novel, topical minocycline formulation for treatment of acne vulgaris. We report that FMX101 4% had an MIC(90) of 0.25 mug/ml and was >/=4-fold more active than comparator antimicrobials against a panel of 98 clinical Cutibacterium acnes isolates. The panel was diverse by clonal complex and sequence type, having 20 novel multi-locus sequence types including clonal complexes and sequence types associated with acne (CC1, CC3, and CC4; ST1 and ST3). Some isolates were phenotypically resistant to clindamycin (6.1%), erythromycin (14.3%), and tetracycline (2.0% intermediate resistance). Six isolates (6.4%) carried a mutation in the quinolone resistance-determining region of gyrA. With C. acnes, spontaneous resistance to FMX101 4% occurred at frequencies ranging from </=5 x 10(-9) to <1 x 10(-8); mutations were identified in rpsJ, a gene encoding 30S ribosomal protein S10. No mutant exhibited a minocycline MIC above 0.5 mug/ml. No second-step mutation in previously isolated mutants or strains containing rpsJ +/- 16S rRNA mutations was detected following minocycline challenge. Minocycline retained antibacterial activity against C. acnes over 15 multiple passages; thus, no selective growth advantage for minocycline-resistant mutants occurred under the experimental conditions. FMX101 4% has the potential to retain the favorable resistance profile of minocycline in diverse C. acnes isolates while providing the benefits of a topical formulation for treatment of acne vulgaris. Twit Text FOAVip Susceptibility of Cutibacterium acnes to topical minocycline foam ????Anaerobe http://www.kidney.de/pget.php?&tw=1&pmid=32058277 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32058277 #FOAvip English Wikipedia <ref>{{Cite pmid|32058277}}</ref> Susceptibility of Cutibacterium acnes to topical minocycline foam #MMPMID32058277 Sutcliffe J; McLaughlin R; Webster G; Read AF; Drlica K; Elliott R; Stuart I Anaerobe 2020[Apr]; 62 (ä): 102169 PMID32058277show ga FMX101 4% minocycline foam (FMX101 4%) is a novel, topical minocycline formulation for treatment of acne vulgaris. We report that FMX101 4% had an MIC(90) of 0.25 mug/ml and was >/=4-fold more active than comparator antimicrobials against a panel of 98 clinical Cutibacterium acnes isolates. The panel was diverse by clonal complex and sequence type, having 20 novel multi-locus sequence types including clonal complexes and sequence types associated with acne (CC1, CC3, and CC4; ST1 and ST3). Some isolates were phenotypically resistant to clindamycin (6.1%), erythromycin (14.3%), and tetracycline (2.0% intermediate resistance). Six isolates (6.4%) carried a mutation in the quinolone resistance-determining region of gyrA. With C. acnes, spontaneous resistance to FMX101 4% occurred at frequencies ranging from |Anti-Bacterial Agents/*administration & dosage[MESH] |Drug Resistance, Bacterial[MESH] |Genotype[MESH] |Gram-Positive Bacterial Infections/microbiology[MESH] |Humans[MESH] |Microbial Sensitivity Tests[MESH] |Minocycline/*administration & dosage[MESH] |Multilocus Sequence Typing[MESH] |Mutation[MESH]Susceptibility of Cutibacterium acnes to topical minocycline foam (epmc).pdf DeepDyve Pubget Overpricing